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ABSTRACT
Zheng, Faye H. Ph.D., Purdue University, August 2016. The Design and Statistical Analysis of Single-Cell RNA-Sequencing Experiments. Major Professor: R.W.
Doerge.
Next-generation DNA- and RNA-sequencing (RNA-seq) technologies have expanded rapidly in both throughput and accuracy within the last decade. The momentum continues as emerging techniques become increasingly capable of proﬁling
molecular content at the level of individual cells. One goal of this research is to put
forward best practices in the design of single-cell RNA-sequencing (scRNA-seq) experiments, speciﬁcally as it relates to choices regarding the trade-oﬀ between sequencing
depth and sample size. In addition to general guidelines, an interactive tool is presented to aid researchers in making experiment-speciﬁc decisions that are informed
by real data and practical constraints. Further, a new approach to the modeling and
testing of diﬀerential gene expression in scRNA-seq data is proposed, which notably
incorporates salient features (e.g. highly zero-inﬂated expression values) of single-cell
transcription that are otherwise obscured at the tissue level. As single-cell technologies oﬀer an unprecedented window into cell-to-cell heterogeneity and its biological
consequences, it is essential that suitable approaches are adopted for both the design
and analysis of these experiments.
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1. INTRODUCTION
Next-generation DNA- and RNA-sequencing technologies have expanded rapidly in
both throughput and accuracy within the last decade. The momentum continues as
emerging techniques become increasingly capable of proﬁling molecular content at the
level of individual cells. Cell-to-cell heterogeneity and its biological consequences are
now the focus of many unprecedented studies capable of illuminating the dynamic
nature of single cells. Recent investigations have pushed the boundaries of understanding structural changes in cancer genomes, varying paths of cell diﬀerentiation,
and ﬁner mechanisms of cell regulation. Like many emerging technologies, the statistical analysis of single-cell data currently remains in the exploratory stage, but
is poised to shift towards informative tests of speciﬁc hypotheses. Moving forward,
thoughtful decisions regarding experimental design are essential if these experiments
are to be maximally eﬃcient, reproducible, and informative. One of the overarching
goals of this research is to put forward best practices in the design of single-cell RNAsequencing (scRNA-seq) experiments, speciﬁcally as it relates to choices regarding
the trade-oﬀ between sequencing depth and sample size.
Aside from experimental design, the statistical analysis of scRNA-seq data itself
invites a critical revisitation of standard RNA-seq methods. In particular, the modeling and testing of diﬀerential gene expression is currently addressed by implementing
a variety of standard and available methods which incorporate salient features of
tissue-level RNA-seq data. Because these current methods do not adequately extend
to RNA-seq data from single cells, another goal of this work is the development of
a novel approach for the detection of diﬀerential gene expression signatures between
subpopulations of single cells; this is essential, given the great interest in understanding cell-to-cell heterogeneity.

2
1.1

History of Sequencing Technologies
The aim of DNA sequencing technologies is to decipher the order of nucleotides

(i.e., the adenine, thymine, cytosine, and guanine units, collectively called bases) in a
DNA molecule, which constitutes the genetic code of an organism. Sanger sequencing
marked the inception of these technologies, and culminated in the completion of the
landmark Human Genome Project in 2001 [Lander et al., 2001]; this feat ushered in
the age of genomics. The second wave of sequencing methods, beginning in 2004 and
widely used today, brought with it substantial increases in speed and throughput.
The parallel, automated nature of the process, commonly dubbed “next-generation
sequencing” (NGS), produces millions of sequences concurrently, increasing throughput by many orders of magnitude [Metzker, 2010]. In addition, these high-throughput
sequencing technologies have signiﬁcantly decreased the cost of sequencing, which is
now less than ten cents per megabase [National Human Genome Research Institute,
2015].

1.2

Next-Generation Sequencing: From Tissues to Cells
NGS procedures have become more aﬀordable, ubiquitous, even routine, and

yet the ceiling of optimization is being pushed still further. Capitalizing on wellestablished NGS platforms, recent technological advances have enabled a dramatic
scaling down in the amount of genomic starting material required to produce sequence information. Indeed, it is now possible to sequence at the level of individual
cells. In the past, genomic data generated by NGS procedures typically came from
aggregating the entire population of thousands to millions of cells within a tissue
(Figure 1.1), even though it is increasingly understood that genetic heterogeneity is
the norm rather than the exception [Eberwine et al., 2014]. The bulk pooling of cell
populations averages out diﬀerences between the behaviors of individual cells, blends
together the patchwork composition of cells within certain tissues, and obscures the
dynamic nature of cellular function. Sequencing at the single cell level allows for
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the dissection of genetic heterogeneity with the intent of obtaining a much higher
resolution of information.

Figure 1.1. Bulk tissue sample (left) is used to obtain sequence information on an aggregate of the entire population of thousands to millions of
cells within a tissue. A single-sampled cell (right) allows for genetic heterogeneity to be dissected by obtaining sequence information on each cell
within the population of cells.

The ability to ask questions of individual cells has motivated a ﬂood of research in
pursuit of insights into both new and longstanding questions that previously could not
be answered from bulk tissue analysis [Shapiro et al., 2013]. Living tissues are often
comprised of a multitude of cell types with diﬀerent lineages, stages of development,
and function within the tissue. Cell lineage is particularly important in the study of intratumor heterogeneity; several single-cell sequencing studies have shown that tumor
development occurs through a series of somatic mutations that drive groups of cells
into distinct clonal subpopulations, each with its own mutational signatures and even
drug response [Navin et al., 2011, Alexandrov and Stratton, 2014, Yates and Campbell, 2012]. Single-cell technologies have also made it possible to detect the presence
of cancer by way of rare circulating tumor cells in blood specimens [Ramsköld et al.,
2012, Cann et al., 2012]. Aside from cancer applications, the sensitivity of single-cell
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sequencing allows for the isolation and characterization of complex microbes in the
environment, oﬀering a way to detect low-abundance and sometimes unculturable
species [Yilmaz and Singh, 2012, Blainey, 2013]. The prevalence of somatic mosaic
mutations in individual neurons of the human brain has recently been highlighted
[McConnell et al., 2013], setting the stage for studying the roles of this mosaicism
for neurodevelopmental diseases [Poduri et al., 2013]. Applications of NGS have even
reached the realm of reproductive health, where single-cell sequencing has demonstrated its utility in diagnosing potential problems with in-vitro fertilized embryos
prior to implantation, and in oﬀering a viable non-invasive alternative for prenatal
testing [Yan et al., 2013, Chandrasekharan et al., 2014]. Promising ventures have
also been made into single-cell epigenomics [Lorthongpanich et al., 2013], proteomics
[Willison and Klug, 2013], and metabolomics [Rubakhin et al., 2013], thus rounding
out the astounding range of possibilities for single-cell NGS technologies.

1.3

RNA-Sequencing

1.3.1

Basics of RNA

RNA-sequencing (or RNA-seq) is one application of NGS high-throughput technologies, and is the primary focus of this work. RNA-seq is used to measure gene
expression by sequencing and quantifying a sample’s mRNA content. To fully understand the context of RNA-seq and what its measurements represent, it is instructive
to review how genetic information ﬂows from DNA to biological function, as explained
by the classic Central Dogma of Biology (Figure 1.2) [Crick et al., 1970]. DNA, located in the nucleus of every cell, consists of a sequence of nucleotides that comprise
the organism’s genetic code. Genes are speciﬁc sections of DNA that encode for a
particular protein or function. Through the process of transcription, the genetic information in DNA becomes copied into complementary strands of messenger RNA
(mRNA). These aptly named mRNA deliver the copied genetic information to the
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1.3.2

The Process of RNA-Seq

The RNA-seq process begins with the extraction of mRNA from the given biological starting material. In original applications involving the analysis of bulk tissue,
whole tissues are simply obtained by sampling, dissecting, or biopsying the organism
of interest. For single-cell investigations, this primary tissue is ﬁrst disassociated into
its constituent cells, which must be isolated intact; cells that pass screening procedures for viability are ﬁnally submitted for further processing.
Single cell isolation does not yet have a single standard procedure and remains
an active area of development and reﬁnement [Saliba et al., 2014]. At the most rudimentary level, cells may be isolated by micromanipulation under a microscope using
a patch pipette or nanotube. Despite the obvious limitations of low throughput, high
risk of disruption, and the potential for experimental bias towards certain morphologies, manual handling is still employed for targeted applications, such as for rare cells
[Shapiro et al., 2013].
The single cell gene expression applications considered here rely on the far more
prevalent automated methods for isolating cells at high volume. For example, the
technique known as ﬂuorescence-activated cell sorting (FACS), which involves ﬂowsorting cells that are labeled with ﬂuorescent antibodies [Shapiro, 2005], has achieved
popularity due to its wide availability on commercial platforms [Saliba et al., 2014].
Another rapidly expanding and highly eﬃcient approach is the use of automated
microﬂuidic devices that compartmentalize cells into low-volume chambers and simultaneously screen them for viability. Current iterations of this technology oﬀer
standard plates with 96-well capacity for the parallel isolation of cells. However, 800well plates are on the near horizon [Fluidigm, Inc., 2015], signaling the imminent need
for statistical and computational tools that can accommodate this rapidly expanding
scale of data.
Once the initial biological material has been obtained, whether from a tissue or
individual cell, the mRNA that is extracted must be reverse-transcribed into comple-
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mentary strands of cDNA. This step is required due to the fact that DNA molecules
are much more biologically stable and resistant to degradation; in fact, for this reason all NGS technologies are solely designed for sequencing DNA, rather than RNA
directly. This cDNA acts as input to the remaining RNA-seq protocol.
While there are several NGS sequencing platforms available that are capable of
performing RNA-seq (e.g., SOLiD, Roche 454, Paciﬁc Biosciences, Ion Torrent), by far
the most successful and widely adopted is the Illumina platform, whose “sequencing
by synthesis” (SBS) chemistry has produced approximately 90% of global sequencing
data, by the company’s own accounts [Illumina, Inc., 2015a]. The general workﬂow,
speciﬁc to the Illumina platform, can be broken into four basic steps: library preparation, cluster ampliﬁcation, sequencing, and read alignment (Figure 1.3) [Illumina,
Inc., 2015b].
Following reverse-transcription of the extracted mRNA, the resulting cDNA undergoes preparation for sequencing (Figure 1.3A). Speciﬁcally, the cDNA is randomly
fragmented into millions of pieces, and specialized adapters are ligated to the ends
of each piece. The resulting collection of fragments comprise the units which will
get sequenced, and hence is termed the ‘sequencing library’. The adapters on each
fragment help attach them onto the surface of the ﬂow cell within the sequencing machine (Figure 1.3B). Each fragment is copied thousands of times through many cycles
of ‘bridge ampliﬁcation’, creating distinct clusters containing identical copies of the
same fragment. Sequencing by synthesis, speciﬁc to the Illumina platform, proceeds
in the following manner (Figure 1.3C): ﬂuorescently labeled nucleotides are washed
onto the surface of the ﬂow cell; as each nucleotide binds to a complementary base
on a fragment cluster, its ﬂuorescent signal is emitted and read as a digital image to
identify the base; this wash-and-scan cycle is repeated one-by-one for each consecutive base, for all fragment clusters in parallel, to generate milions of sequenced reads
of about 125 to 300 bases each in length. From this point in the workﬂow, computational tools are used to map each read to its appropriate location on a reference
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genome, a process called sequence alignment. If no reference genome is available, the
reads can also be assembled de novo (Figure 1.3D).
Gene expression is ﬁnally quantiﬁed by counting the number of reads that map to
the genomic feature of interest, e.g., genes [Wang et al., 2009, Oshlack et al., 2010,
Mortazavi et al., 2008]. The data are typically represented as a matrix, in which
genes constitute row labels, samples constitute column labels, and values within the
matrix are read counts representing the expression of a particular gene in a particular
sample (Table 1.1). Samples can represent either bulk tissue samples or single-cell
samples; in either case, the matrix representation is the same.

Table 1.1
RNA-seq data are typically represented as a matrix of the following form.
The values yig represent the expression of gene g in sample i. The library

sizes, Li = G
g=1 yig , are the total number of reads aligned to sample i
across all genes.

Sample 1

Sample 2

...

Sample N

Gene 1

y11

y21

...

yN 1

Gene 2

y12

y22

...

yN 2

...

...

...

...

...

y1G

y2G

...

yN G

L1

L2

...

LN

Gene G

1.3.3

Bulk Tissue vs. Single Cell Protocols

The workﬂow described in Figure 1.3 is shared between the RNA-sequencing of
bulk tissues and that of individual cells. However, the single-cell procedure requires
one important extra step: additional ampliﬁcation of the cDNA during library prepa-
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ration. Speciﬁcally, this ampliﬁcation is applied to the fragments of genomic cDNA
prior to adapter ligation (Figure 1.3A), and is done repeatedly until the DNA concentration matches the requirements of the sequencing technology. The amount of ampliﬁcation required can often be around one million-fold, substantially more magnitudes
beyond what is necessary for bulk tissue sequencing. This is a direct consequence of
the scant amount of biological material that single cells provide.
Ampliﬁcation comes with the unfortunate cost of biases that compromise quantitative accuracy, most often in the form of nonlinear distortions of transcript abundance and preferential ampliﬁcation of certain sequence patterns. Ampliﬁcation biases have previously been noted with traditional bulk RNA-seq, and a number of
methods exist to correct the resulting data. The additional cDNA ampliﬁcation of
single-cell quantities exacerbates this already-existing problem and has required this
issue to be revisted. Recently, Islam et al. [2014] developed an inventive technique in
which unique labels are attached to each single-cell cDNA molecule prior to ampliﬁcation. These labels, called unique molecular identiﬁers (UMIs), mark as distinct each
molecule originally present in the sample. Following ampliﬁcation, one can quantify
gene expression by counting only the number of distinct UMIs aligned to each genomic feature, rather than counting all the ampliﬁed reads that are aligned. Since
this method eﬀectively counts only the original, unampliﬁed molecules, ampliﬁcation
noise may be avoided altogether.
Ampliﬁcation biases, combined with the delicate process of isolating single cells
and the technical diﬃculty of sequencing a miniscule pool of transcripts, contribute
substantially to the high levels of technical noise seen in scRNA-seq data. While not
addressed directly in this work, these challenges that set single-cell sequencing apart
are important considerations in other aspects of the design and statistical analysis of
single-cell experimental data.
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2. EXPERIMENTAL DESIGN OF SCRNA-SEQ EXPERIMENTS
Two leading questions are central to the design of a scRNA-seq experiment: the depth
at which to sequence each cell, and how many cells to sequence. These decisions are
aﬀected by the biological question being considered, and by the tradeoﬀs imposed by
practical ﬁnancial constraints.

2.1

Sequencing Depth and Replication
The currently accepted deﬁnition of sequencing coverage originated from Lander

and Waterman [1988]. This work ﬁrst deﬁned theoretical coverage as LN/G, where L
is the length of each sequencing read, N is the number of high-quality reads aligned
to the genome, and G is the total number of bases in the genome. In other words,
this is the expected number of times that a given base is covered by a read. It is often
reported as a technical speciﬁcation of a sequencing experiment (e.g., samples were
sequenced at 1× or 30× coverage). The terms coverage, depth, and depth of coverage,
all referring to this deﬁnition, are used interchangeably in the literature. In practice,
particularly in RNA-seq, is often thought of as simply the total number of reads
that are mapped to the genome and then counted as gene expression measurements
(Figure 2.1). This will be the usage of the term subsequently adopted here.
The higher the sequencing depth, the more accurate the quantiﬁcation of gene
expression. This stems from the imperfect nature of the sequencing technology, in
which reads are short and contain errors. At higher sequencing depths, alignment
tools are better able to distinguish a base that is sequenced in error to a base that
is a true variant from the reference genome. For example, a base that is covered by
twenty reads, of which the base call consistently varies from the reference genome
in a majority of those reads, is much more likely to be a true genetic variant than
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Figure 2.1. In the context of RNA-seq, sequencing depth most commonly
refers to the total number of reads that are mapped to the genome and
subsequently quantiﬁed as gene expression measurements.

a sequencing error. At lower depths, this distinction is harder to make [Sims et al.,
2014]. In addition, there exist genes with low expression levels that are hence represented by fewer mRNA transcripts in the biological pool. Higher sequencing depths
increase the likelihood that even these rare transcripts are sequenced. To illustrate,
in Figure 2.1, a reduction to the pool of reads could lead to gene B being missed
completely, whereas the remaining sequencing real estate becomes concentrated in
the more highly expressed genes A and C.
Despite the clear beneﬁts of sequencing at suﬃciently high depths, researchers
would be remiss to simply sequence as much as possible. Higher sequencing depths are
accompanied by higher costs, as sequencing machines can accommodate only a limited
number of reads per expensive run. Moreover, it has been shown that there exists
a point of diminishing returns at which continuing to increase the sequencing depth
fails to yield substantially more genomic information. This is demonstrated in socalled ‘saturation curves’, which plot the number of genes detected in a given sample
against an increasing number of reads. The saturation curves in Figure 2.2, generated
from the R package NOISeq [Tarazona et al., 2011], demonstrate this property using
randomly chosen samples from a real scRNA-seq data set on human prostate cell lines
(described in Section 2.2).
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Figure 2.2. Saturation curves of randomly chosen samples from a real
scRNA-seq data set on human prostate cancer cell lines. Each curve plots
the number of detected genes, deﬁned as genes with counts greater than 3,
against against sequencing depth for a cell sample. For a full description
of how this plot was generated, see Tarazona et al. [2011]. As the number
of reads increase, the number of genes detected also increases, but begins
to taper oﬀ. This pattern is typical of both bulk and single-cell RNA-seq
data.

Sequencing depth is but one piece of the puzzle when designing a scRNA-seq
experiment. A second consideration of great practical interest to a researcher is
the optimal number of cells to sequence. The pricing structure of the sequencing
technology links these two choices of depth and replicates. As mentioned previously,
the sequencing reaction occurs on the surface of a ﬂow cell within the machine. In
practice, these ﬂow cells are composed of multiple independent lanes, with a limit to
the number of reads that can be sequenced per lane. For example, the various Illumina
systems can accommodate between 80 to 200 million reads per lane, depending on
the choice of read length. Importantly, the largest cost of a sequencing experiment
is in the price per lane. Therefore, given the ﬁnancial constraints of an experiment,
there exists a tradeoﬀ between sequencing fewer cells with more reads each or more

14
cells each at lower depths. The optimal balance point is the question of interest,
speciﬁcally in the context of detecting diﬀerential expression.
The question of optimizing the trade-oﬀ between sequencing depth and biological replicates has been asked previously of bulk RNA-seq tissues [Liu et al., 2014].
However, here the focus has changed, in keeping with the shift in context going from
designing experiments for bulk samples as opposed to single cells. While bulk RNAseq studies often limit themselves to around a dozen samples (sometimes more but
often less) over two or more treatments, single-cell studies are seen to involve hundreds to occasionally thousands of cells that are considered biological replicates. This
is partially due to the enormous reduction of labor and cost involved in isolating
single cells as opposed to collecting tissue samples from whole organisms. It is also
partially a necessity; a large number of cells is needed to characterize cell populations
and to counter the variability of each individual cell. Hence, while in bulk RNAseq the popular recommendation is to always obtain as many biological replicates
as possible, for single-cell applications, the question remains whether there may be
a saturation point beyond which more replicates is not necessary. With respect to
sequencing depth, the standard is to use around 30 million reads per sample for bulk
RNA-seq diﬀerential expression studies. By contrast, the number of reads per single
cell, though markedly less than what is used for bulk samples, still varies substantially
between studies [Stegle et al., 2015]. For example, Jaitin et al. [2014] used around
20, 000 reads per cell for over 1, 500 cells, while Mahata et al. [2014] sequenced an
average of 16 million reads per cell for each of around 90 cells.
There is currently no accepted rule of thumb or guide that either empirically or theoretically instructs researchers about the optimal choice of sequencing depth and/or
replicate number. Certainly, understanding this relationship has great value when
designing a scRNA-seq experiment. Here, a simulation study attempts to provide
guidance by investigating the eﬀect of diﬀerent combinations of sequencing depths
and numbers of replicates on the detection of diﬀerential gene expression.
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2.2

Procedure for Simulating scRNA-seq Data
The starting point of any simulation study is the choice of how to generate simu-

lated data in a way that adequately mimics real data. Throughout this work, count
data are all simulated from a zero-inﬂated negative binomial (ZINB) distribution,
with gene-wise parameters extracted from a real scRNA-seq dataset. Speciﬁcally,

for each gene g, take ȳg to be the mean of the non-zero counts; λg = ȳg / g ȳg is
then the proportion of all read counts originating from gene g, and can be considered the baseline rate of expression from gene g. The NB dispersion is calculated as
φg = (s2g − ȳg )/ȳg2 , where s2g is the variance of the non-zero counts. Also recorded are
the gene-wise proportions of zero counts, pg . Parameters are sampled in gene-wise
triplets of {λg , φg , pg } to be used to generate simulated gene counts.
To introduce diﬀerential expression on a select proportion of genes, coeﬃcients
βg reﬂecting the group eﬀect are drawn as βg ∼ logNormal(2, 1) for diﬀerentially
expressed genes, while coeﬃcients for non-DE genes are set to 0. The log-linear
model for the expected count μgi of gene g in sample i is
log(μgi ) = λg + xi βg + log(mi )

(2.1)

where xi indicates the group membership of the ith sample and mi is the sample i
library size included as an oﬀset. Finally, counts are simulated as ygi ∼ NB(μgi , φg ),
with a proportion of counts for each gene set to zero with probability pg to mimic
the zero-inﬂation prevalent in real scRNA-seq data. Figure 2.3 visually demonstrates
that the mean-variance plot of the simulated data suitably mimics that of the original
data from which the simulation parameters were sampled.

Real scRNA-Seq Prostate Dataset
All simulated datasets in this work are based on a real scRNA-seq dataset from an
experiment involving human prostate cancer cell lines, henceforth referred to simply
as the “prostate” dataset. The dataset is comprised of a treatment group containing
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Figure 2.3. Count data from a real scRNA-seq experiment (left) provide
the parameters that are used to generate simulated gene counts (right).
Mean-variance plots of the simulated gene expression data suitably mimic
that of the original data from which the simulation parameters were sampled.

65 cells in which a gene implicated in prostate cancer was knocked out, and the
negative control group consisting of 76 cells to which no treatment was applied. Each
cell underwent the standard process of cell capture, viability screening, and reversetranscription. Paired-end libraries were prepared and sequenced on an Illumina HiSeq
2500 machine at an average depth of 1 million reads per cell. Following quality control,
alignment, and expression quantiﬁcation, the resulting count data exhibited a middle50% of library sizes ranging from 0.85 to 1.3 million read counts. The original data
comprised 36,135 sequenced genes, many of which exhibit very low expression levels.
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Adopting a standard practice in the literature, only the genes that have average counts
of at least 5 across all cells are considered, resulting in 10,854 remaining genes.

Sequencing Depth Resampling
In simulations that follow, sequencing depth is treated as an experimental feature
whose eﬀect on the outcome of interest is to be studied. To this end, it is necessary
to vary this parameter between otherwise comparable datasets. This process is referred to as “resampling” in general; speciﬁcally, “downsampling” or “subsampling”
describes the process of generating datasets to lower depths.
Sequencing depth generally refers to the number of reads that are sequenced in an
experiment. Recall that the library size is the total number of sequencing reads that
are successfully mapped to a sample. The observed diﬀerence between raw sequencing
depth and the ﬁnal library size is due to a number of factors that cause a proportion
of reads to be discarded. These factors include quality-control ﬁltering, removal of
non-mRNA reads (e.g., ribosomal RNA or other artifacts), and reads that fail to map
unambiguously to the reference genome. Library sizes are therefore not equivalent
to sequencing depth; however, they can reasonably act as a proportionate proxy. It
has been argued by Robinson and Storey [2014] that in simulation applications that
require subsampling reads in order to perform identical analyses on each subsample,
it is functionally identical and substantially more computationally eﬃcient to directly
subsample the read count matrix (Table 1.1) as opposed to the raw unaligned reads.
Hence, in subsequent simulations, the term ‘sequencing depth’ is used to refer to the
‘library size’ as opposed to the ‘number of raw sequencing reads’.
Mulitnomial sampling in the following manner is used to obtain samples of desired
depths D based on a set of original samples. Let yi = {yig }G
g=1 be counts for the G
genes from sample i of the original dataset, with corresponding library size Li =

G
g yig . Let xi = {xig }g=1 be the sample generated from yi with desired depth
Di . The gene counts for xi are drawn from a multinomial distribution with size Di
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and probabilities {yig /Li }G
g=1 . This results in simulated samples xi with the same
probability distribution of gene counts as the originating yi , but with the new depth
of Di .

2.3

Simulations
In order to study the relationship between sequencing depth and replicate number

and their combined eﬀect on detecting diﬀerential expression, datasets of varying
depths and replication levels were generated from the original prostate dataset. The
depths considered for the simulation are D = {0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 1.8}
million reads. The number of replicates per treatment group considered are N =
{10, 20, 30, 40, 50, 60}; that is, N replicates were randomly chosen from each of the
treatment and control groups. 50 datasets were generated for each combination of
D × N (Table 2.1). The R package edgeR was applied to each simulated dataset
to test for diﬀerentially expressed genes. The genes considered ‘truly’ DE are those
testing signiﬁcant in the most ‘robust’ simulation scenario, i.e., the dataset with the
highest sequencing depth (D = 1.8 million reads) and replicates per group (N = 60),
at a false discovery rate (FDR) cutoﬀ of 0.001. Using these ‘true’ DE genes as the
gold standard for comparison, the statistical power of each experimental design may
be calculated as the number of true DE genes that are also detected as DE (true
positives), divided by the total number of true DE genes (positives).
Figure 2.4 (top) shows the statistical power to detect DE genes as a function of
depth and replicates. Increasing the number of replicates substantially and consistently increases statistical power. By contrast, increasing the sequencing depth has
a much smaller eﬀect on power, and plateaus oﬀ after a point. Figure 2.4 (bottom)
depicts the number of diﬀerentially expressed (DE) genes detected for the various
combinations of sequencing depths and replicates per group. Consistently more DE
genes are called as the number of replicates increases, particularly at higher sequencing depths. Increasing the sequencing depth has little to no eﬀect on calling DE genes
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Table 2.1
Simulated datasets are generated from the real prostate dataset, by randomly selecting N replicates per experimental group in the real data,
and resampling counts to the desired depth D. 50 datasets are simulated
for each combination of D × N , and edgeR is applied to obtain lists of
diﬀerentially expressed genes detected in each setting.
Depths (D)
0.1M

0.2M

...

1.8M

10
20
Reps per Group (N )

×50

...
60

at lower replication levels, but has increasing eﬀects at higher replication levels. The
ROC curves in Figure 2.5 depict the eﬀect of sequencing depth on the accuracy of DE
testing for each level of replication. At lower replication levels, increasing the number
of reads has some eﬀect on accuracy, most notably moving away from the very lowest
depths. However, as replication levels increase, more reads hardly contributes at all
to increasing the accuracy of the test. In general, the area under the ROC curve
improves as more replicates are included.
The results depicted in Figures 2.4 and 2.5 are limited in the maximum number of replicates per group that they are able to show, as they are based on direct
subsampling of a real prostate dataset consisting of only 64 replicates for its smaller
experimental group. The eﬀects of greater sample sizes may be observed through generating synthetic data containing higher replicate numbers. This was accomplished
by simulating datasets based on parameters extracted from the same human prostate
scRNA-seq data (as described in Section 2.2). The intended eﬀect was to mimic the
real data in distributional parameters, but with group replicate numbers ranging from
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Figure 2.5. Results from datasets subsampled from the real prostate data,
to varying sequencing depths and replicates per group. A separate ROC
curve is depicted for each of the considered replication levels per group,
and individual lines represent sequencing depths.

20 to 200. As expected, as the number of replicates per group continue to increase,
diminishing returns are observed in both the number of DE genes detected as well as
the statistical power to call true DE genes (Figure 2.6), particularly as the number
of replicates per group reaches into the hundreds. ROC curves for the synthetic data
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(Figure 2.7) demonstrate similar patterns to those in Figure 2.5, in that higher replicates consistently lead to higher areas under the curve, and increasing sequencing
depth has little positive eﬀect beyond the lowest depths.
Observations made here are consistent with what has been suggested previously
with Liu et al. [2014] in bulk RNA-seq studies; that is, the number of biological
replicates has a markedly more positive eﬀect than sequencing more deeply. This
said, for both variables, more is always better, but only up to a point.

2.4

Guiding the Choice of Optimal Experimental Design
Recommendations as to the choice of sequencing depth and replicate number may

oﬀer general guidelines in the way of experimental design. However, the real practical interest for researchers is in the ability to make experiment-speciﬁc decisions that
are informed by the real or expected variability in their data, as well as constraints
such as desired statistical power and budgetary limits. As part of this investigation,
an interactive tool was implemented in a Shiny web application called scDesignApp,
which may be accessed at https://fayezor.shinyapps.io/scDesignApp/. It is
accompanied by an associated R package called scDesign, which may be installed
from GitHub at https://github.com/fayezor/scDesign. Given pilot data, typically based on real data, this tool calculates statistical power and estimates costs for
each of a user-speciﬁed range of experimental designs.
The general workﬂow for the implementation of the scDesign tool is as follows.
First, the user provides a pilot dataset from which parameters will be estimated in
subsequent calculations. These pilot data may be either a small-scale portion of
the planned experiment or related prototype data from similar previous experiments.
Recommendations for pilot data best practices are proposed in Section 2.4.3. To
compare a variety of hypothetical experimental designs, users must specify a range
of sequencing depths and a range of replication levels to be considered. Each combination of depth and replication level constitutes an experimental design. Other
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Figure 2.7. ROC curves for each of the considered replicate numbers per
group. Lines in each curve represent the sequencing depth. Plots were
generated from simulated data generated using distributional parameters
extracted from the human prostate scRNA-seq dataset.

inputs from the user may include the desired statistical power, budget constraint,
false-discovery rate (FDR) to be controlled, and anticipated cost parameters.
Gene-speciﬁc parameters are estimated from the user-provided pilot data, and
statistical power is calculated for each experimental design. Statistical power is ad-
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dressed in two ways. First, an empirical power calculation is performed by simulating
datasets for each design and recording the observed levels of statistical power obtained. Second, a theoretical method implements the power-estimation procedure of
Bi and Liu [2016]. Both statistical power calculation methods are described in Section
2.4.1 in greater detail. Finally, the cost of each experimental design is also projected,
based on the formula and default cost assumptions provided in Section 2.4.2.

2.4.1

Statistical Power Calculation

The utility of the interactive tool comes from employing a dataset that is either
a subset of or representative of a full experiment, and obtaining estimates of what
the statistical power might be to detect diﬀerential expression if the researcher were
to carry out a full experiment of a speciﬁed size. It is therefore important to choose
with care the method of experiment-wide statistical power estimation.
Several methods exist for RNA-seq statistical power calculations that are performed on a gene-by-gene basis, with varying assumptions about the distribution of
the true underlying expression values. For example, Fang and Cui [2011] propose a
formula based on the Wald test for single-gene diﬀerential expression analysis, while
treating the data as Poisson. Hart et al. [2013] treat the data as negative binomial and
derive a formula based on a score test, highlighting the relationship between technical
and biological variability, and using empirical justiﬁcations for how to choose certain
parameters of the formula. Busby et al. [2013] uses a non-central t-distribution to
approximate the statistical power of an experiment, arguing that a normal approximation is reasonable for RNA-seq data; however, such justiﬁcations are generally not
accepted in the general literature, as RNA-seq count data are often known to have
distributions too skewed to be modeled as normal.
What is of most interest, however, is not merely the statistical power of a single
gene, but of experiment-wide power over the tens of thousands of genes measured in an
RNA-seq experiment. Single gene statistical power calculations are often accompanied
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by suggestions for how to pool per-gene powers over an experiment; typically this
involves taking the average, with or without allowing parameters to vary between
genes. However, in situations involving many simultaneous tests as with RNA-seq, it
is necessary to account for this multiple testing using error criterion such as the false
discovery rate (FDR) [Benjamini and Hochberg, 1995].
One procedure for calculating experiment-wide statistical power while controlling
for FDR is proposed in Li et al. [2013a], consisting of a single gene formula for computing statistical power based on several test statistics, and an extension of that
formula to incorporate FDR control. However, the procedure is based on a Poisson
distribution, which is inappropriate for the overdispersion present in RNA-seq experiments involving many biological replicates. The authors try to address this in Li
et al. [2013b] by assuming a negative binomial distribution for the expression counts,
and using a statistical power calculation based on the exact test as used in edgeR
for testing diﬀerential expression between two groups. However, several features of
the procedure render it extremely conservative; for example, statistical power is computed by setting the fold change parameter to be the minimum fold change observed
across all genes deemed diﬀerentially expressed, and similarly setting the dispersion
to the maximum observed. This likely limits the practicality of the procedure.
It is evident that experiment-wide statistical power considerations for RNA-seq
data while controlling FDR is underdeveloped. Reﬂecting on the microarray literature, Liu and Hwang [2007] calculate statistical power at a speciﬁed FDR level by
ﬁnding the rejection region for the test procedure. The authors use t-tests to model
microarray data. The recent Bi and Liu [2016] takes the machinery of Liu and Hwang
[2007] and makes it applicable to RNA-seq data by applying the voom method of the
limma package to ﬁrst transform the count data into normalized log-counts. This
circumvents the direct use of the negative binomial distribution, for which there exist
no analytical relationships between statistical power and sample size, as there are
no closed-form solutions for the maximum likelihood estimate of the NB dispersion.
Due to the applicability of Bi and Liu [2016] to RNA-seq data, its control of FDR to
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account for multiple testing, and its avoidance of computationally-heavy simulations,
this procedure is implemented for the theoretical statistical power calculation in our
experimental design tool. The details of the procedure are as follows, as originally
described in Liu and Hwang [2007] and Bi and Liu [2016].

Theoretical Calculation of Statistical Power
Let H0 and H1 be indicators that the null or the alternative hypothesis is true,
respectively; let Γ be the rejection region of a given test statistic T ; and let π0 be
the assumed proportion of true nulls. Table 2.2, originally shown in Benjamini and
Hochberg [1995], is popularly used to categorize the diﬀerent outcomes of testing G
hypotheses.
Table 2.2
Table of outcomes when testing G simultaneous hypotheses, π0 of which
are true nulls.
Declared non-signiﬁcant

Declared signiﬁcant

Total

H0 is true

U

V

π0 · G

H1 is true

T

S

(1 − π0 ) · G

G−R

R

G

Total

The false discovery rate (FDR) is deﬁned as the expected proportion of false positives
among the rejected hypotheses Benjamini and Hochberg [1995]. That is,
 

V 
F DR = E
R > 0 P (R > 0).
R

(2.2)

Storey [2003] oﬀered a slight modiﬁcation of this to the positive false discovery rate,
deﬁned as

 

V 
pF DR = E
R>0 .
R

(2.3)
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Since it may safely be assumed in genomic studies that there will be at least one
rejection, i.e. that R > 0, pFDR and FDR will be used interchangeably here. By
Bayes rule, (2.3) can be written1 as
P (H0 |T ∈ Γ) =

P (T ∈ Γ|H0 ) · π0
P (T ∈ Γ|H0 ) · π0 + P (T ∈ Γ|H1 ) · (1 − π0 )

(2.4)

In order to control FDR at a given level α, setting equation (2.4) to be less than or
equal to α yields the following relationship with some simple algebra.
α 1 − π0
P (T ∈ Γ|H0 )
≥
1 − α π0
P (T ∈ Γ|H1 )

(2.5)

On the right-hand side, Type I error is in the numerator and statistical power is in
the denominator. The task is to ﬁnd the rejection region Γ so that equation (2.5) is
satisﬁed, hence controlling FDR at level α; statistical power may be computed once
the rejection region is known.
The original application of Liu and Hwang [2007] was intended for microarrays,
in which the data were appropriately assumed to be normal and t-tests could be
applied for two-sample comparisons. However, the method is not directly applicable to
commonly applied tests for RNA-seq data involving a negative binomial distribution,
as there are no closed-form solutions for calculating P (T ∈ Γ|H0 ) and P (T ∈ Γ|H1 ).
As mentioned earlier, Bi and Liu [2016] extended the method to be used for RNA-seq
data by ﬁrst transforming the data to a normalized log-counts per million (log-cpm)
value, as part of the method called voom implemented in the R package limma (Linear
1

The Bayesian interpretation of the pFDR (2.3) is detailed and proven in Theorem 1 of Storey [2003].
Brieﬂy, given G identical tests of the null hypothesis H0 with accompanying test statistics T1 , ...TG
and a given rejection region Γ, pF DR may be rewritten as



V (Γ) 
pF DR = E
R(Γ) ,
R(Γ) 
where V (Γ) = #{null Ti |Ti ∈ Γ} and R(Γ) = #{Ti |Ti ∈ Γ}. P (H0 |T ∈ Γ) represents the probability
of a false positive, given a signiﬁcant test statistic. For the case when G = 1, V (Γ)/R(Γ) must be
either 0 or 1, so it easily follows that pF DR = P (H0 |T ∈ Γ). Storey [2003] show, with proof, that
this result is the same for when G > 1.
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Models for Microarray Data). This approach allows for the derivation of a t-test
based test statistic formula that can subsequently be used in the application of the
original method as before.
In a two-sample comparison, where the interest is to ﬁnd diﬀerentially expressed
genes between two experimental groups, the hypothesis to test for each gene g is
H0g : μg1 = μg2

(2.6)

H1g : μg1 = μg2 ,

(2.7)

where μg1 and μg2 are means of the normalized counts in each group. The t-test
statistic for gene g is


Tg =
sg

Δg
1
n1

+

1
n2

,

(2.8)

where Δg is the scaled eﬀect size, deﬁned as the weighted mean diﬀerence of log-cpm
values between groups, and sg is the pooled standard deviation. To accommodate
the practical situation where genes may exhibit diﬀerent parameters, assume that the
eﬀect size Δg for each gene follows a normal distribution
2
), denoted by π1 (Δg ),
Δg ∼ N (μΔ , σΔ

(2.9)

and the variance of log-cpm values follows an inverse gamma distribution
σg2 ∼ InvGamma(a, b), denoted by π2 (σg ).

(2.10)

The average statistical power across all genes may be written as an integral over these
distributions,

P (T ∈ Γ|H1 ) =

P (T ∈ Γ|H1 , Δg , σg )π1 (Δg )π2 (σg )dΔg dσg .

(2.11)

Putting (2.11) into equation (2.5), it follows that FDR is controlled at level α when
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P (T ∈ Γ|H0 )
α 1 − π0
≥
1 − α π0
P (T ∈ Γ|H1 )

P (T ∈ Γ|H0 )
P (T ∈ Γ|H1 , Δg , σg )π1 (Δg )π2 (σg )dΔg dσg
P (|Tg | > c|H0 )
= 
P (|Tg | > c|H1 , Δg , σg )π1 (Δg )π2 (σg )dΔg dσg
= 

(2.12)

Using the knowledge that Tg is distributed as a central t-distribution under the null
and a non-central t-distribution under H1 , the denominator in (2.12) is

1−
Tn1 +n2 −2 (c|θg )π1 (Δg )π2 (σg )dΔg dσg

+
Tn1 +n2 −2 (−c|θg )π1 (Δg )π2 (σg )dΔg dσg ,

(2.13)

where θg is the non-centrality parameter deﬁned as
Δ
 g

θg =
σg

1
n1

+

1
n2

,

(2.14)

and the numerator in (2.12) equals
P (T ∈ Γ|H0 ) = P (|Tg | > c|H0 ) = 2 · Tn1 +n2 −2 (−c).

(2.15)

Once the critical value c has been obtained which satisﬁes the relationship in (2.12)
for a given level α and proportion of nulls π0 , statistical power may be calculated
from equation (2.13) for a speciﬁc sample size.
The practical implementation of this method based on pilot data is achieved by
ﬁrst simulating a scRNA-seq count dataset as described in Section 2.2, with simulation parameters drawn empirically from the user-submitted pilot data. These counts
are normalized to log-cpm by applying voom/limma as previously described, and are
used to estimate the hyperparameters μΔ , σΔ , a, and b which characterize π1 (Δg ) and
π2 (σg ). These characterized distributions can ﬁnally be used to solve the integrals
necessary for computing statistical power.
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Empirical Calculation of Statistical Power
In order to double-check how reasonable the theoretical statistical power calculation is, scDesign also implements an empirical power calculation based fully on
simulations. This is done by ﬁrst extrapolating the given pilot data to each desired
experimental design setting. That is, parameters drawn from the pilot data are used
to simulate a new dataset with the desired sequencing depth and number of replicates per group and containing a known set of diﬀerentially expressed genes. The
R package edgeR is then applied to test for diﬀerential expression, and the resulting
adjusted p-values are used to obtain the statistical power. Speciﬁcally, statistical
power is calculated as the number of genes determined signiﬁcant at a speciﬁed FDR
that are truly DE (true positives), divided by the total number of truly DE genes
in the simulated dataset (positives). This is repeated a number of times, and the
average of statistical powers in each iteration is taken to be the empirical calculation
of statistical power for the given experimental design. Figure 2.8 shows that for a
given depth, the theoretical and empirical estimates of statistical power are similar,
with empirical calculations being slightly more conservative. While a statistical power
of 0.8 is a typical standard target for experiments, such levels of power are harder
to achieve for scRNA-seq data, which are often zero-inﬂated with higher variability
among replicates even of the same treatment group.
A few remarks bear noting. First, the empirical statistical power calculation inevitably reﬂects the power of the method chosen to test diﬀerential expression, in
this case edgeR. Other methods, for example DESeq2, SCDE, or limma, among others,
will likely yield diﬀerent power estimates. edgeR was chosen for its useability on
data simulated to mimic scRNA-seq data; other attempted methods either yielded
substantially lower statistical power or were computationally intractable for large
numbers of replicates. Second, the empirical power calculation is signiﬁcantly more
computationally intensive than the theoretical power calculation, as it involves applying edgeR to each experimental design a repeated number of times. Hence, while
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tiplexing, and equipment. Attolini et al. [2015] incorporate read-speciﬁc costs in the
following equation:
cost = (c0 × N ) + (c1 × 2rDN ),

(2.17)

where N is the number of samples, each associated with a ﬁxed cost c0 . 2r denotes
the read length for paired-end experiments, D the number of reads per sample, and
c1 the cost per read.
Building on (2.17) to incorporate costs speciﬁc to single-cell experimental designs,
the following cost function is proposed. Let N , as before, denote the number of
samples, in this case individual cells, with a per-cell cost of ccell . These cells are
captured onto plates which hold a default 96 cells at a time, at a per-plate cost of
cplate . This may be adjusted to a higher number of cells per plate, which may soon
increase to as many as 800 cells per plate, as high-throughput cell capture protocols
become more widely available. In addition to cell and plate costs, there are also
per-lane costs clane , where each lane can accommodate a maximum number of reads,
max. Finally, there may be other miscellaneous costs to be captured in cf ixed .
cost = (ccell × N ) + (cplate × N/96) + (clane × N D/max) + cf ixed

(2.18)

A practical adjustment to the cost function is to account for ineﬃciencies in the
capturing of cells and the sequencing of reads. That is, there may be some proportion
of cells on the 96-well capture plates that are captured incorrectly or do not pass a
viability screen. If pcapture denotes the capture eﬃciency, an input of N cells will result
in N × pcapture cells being used in the analysis. In addition, there is typically some
proportion of sequenced reads that do not get aligned and are hence not quantiﬁed;
reasons for this include the ﬁltering of reads that do not pass quality control, ambiguously mapping reads, or reads from artifacts such as rRNA rather than genomic
features of interest. Let pseq denote the sequencing eﬃciency, so that D × pseq is the
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amount of sequenced reads that align successfully and thus quantiﬁed. The following
cost function incorporates these adjustments.
cost = (ccell × N ) + (cplate × N/96 × pcapture )

(2.19)

+ (clane × N D/max × psample × pseq  + cf ixed
The costs of cell, plate, and lane may be chosen with real experiments as a guide.
Table 2.3 presents some typical costs associated with various stages of the scRNA-seq
workﬂow, from cell capture to sequencing; these numbers are based on the actual
costs of the prostate data described in Section 2.2. Per-cell costs may include kits for
cDNA dilution and library prep; per-plate costs may cover plate reagents as well as
the plate itself; per-lane costs comprise the costs of the sequencing itself, depending
on read length and paired- or single-end sequencing; and ﬁxed costs may include
items such as assay tubes, viability kits, and labor. The scDesign tool allows for
the speciﬁcation of the following default parameters: costs per cell, plate, and lane
are respectively $1200, $20, and $2000; ﬁxed costs per experiment are $1200; and the
maximum number of reads per lane is 96 million. Again, these values are based on
the observed costs of the prostate dataset in particular, but may vary widely across
diﬀerent cell types, experimental platforms, and sample preparation protocols.

2.4.3

Pilot Data

Researchers often elect to ﬁrst sequence a handful of replicates at a lower depth
to get a sense of their data before committing to an expensive full experiment. The
utility of our tool is that it requires only the pilot data to estimate what the statistical
power would be in a full imagined experiment; it does so by taking parameters learned
from the pilot dataset to extrapolate the data to “full” size, and using the full data
as a basis for calculations. A natural question might be what is the eﬀect of the size
of the pilot data on the ability of the extrapolations to accurately recover properties
of the full dataset.
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Table 2.3
Some typical costs associated with various stages of the scRNA-seq workﬂow, from cell capture to sequencing; these numbers are based on the
actual costs of the prostate data described in Section 2.2.

Cell Isolation

Library Prep

Sequencing

Item

Cost

96-well plates

$700/ea

Instrument reagents

$440/plate

Viability kit

$400

Library prep kit

$12.50/cell

Other (reagents, tubes)

$305

HiSeq Rapid PE 100bp

$1990/lane

Multiplexing

$300/two lanes

To investigate this, a full-size dataset was simulated with the approach described
in Section 2.2, and relying on parameters taken from the prostate scRNA-seq data.
The experimental design of these full data consist of two hundred replicates per
group at depths of two million. There are ten thousand genes, one thousand of which
exhibit true diﬀerential expression. edgeR was applied to detect DE genes, with
results serving as a baseline for comparison in later analyses of pilot datasets; 647
genes were detected as DE, with a true positive rate (TPR) of 0.625 and false positive
rate (FPR) of 0.002.
Pilot datasets were obtained from the full-sized dataset, by down-sampling to a
range of smaller experimental designs in a similar fashion as Section 2.2. Speciﬁcally,
the number of replicates per treatment group considered are N = {5, 10, 25, 50, 10, 150,
200}, and the depths considered are D = {0.1, 0.25, 0.5, 1, 1.5, 2} million reads. 20
datasets were generated for each combination of N × D. To extrapolate each pilot
dataset back to full size while keeping any original diﬀerential expression patterns,
the simulation procedure of Section 2.2 was adapted to allow the estimation of group-
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depth, show how accurately extrapolations from pilot datasets of each size recover
the true DE genes simulated in the full dataset. As expected, extrapolations perform
much better for pilot datasets with higher replication levels, without much diﬀerence
between depths.
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Figure 2.10. ROC plots, one for each replication level with lines representing sequencing depth, show how accurately extrapolations from pilot datasets of each size recover the true DE genes simulated in the full
dataset.

Concordance plots shown in Figure 2.11 depict the fraction of matching genes in
a list of top k genes, identiﬁed in the extrapolated datasets as compared to the full
dataset, with k from 1 to 100. Each plot shows results for one depth setting, with
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Concordance between detected and true gene rankings
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Figure 2.11. Concordance plots depict the fraction of matching genes
in a list of top k ranking genes, identiﬁed in the extrapolated datasets
as compared to the full dataset. Each plot shows results for one depth
setting, with lines representing the numbers of replicates per group.

lines representing the numbers of replicates per group. The interpretation of this
plot is that the higher the concordance, the better the extrapolated dataset was at
reproducing the top gene rankings of the full dataset. Notice the clear separation
between the abilities of replication levels above 100 as compared to lower levels,
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with respect to recovering the “true” diﬀerential expression patterns of the full data;
this eﬀect is apparent in both the ROC and concordance plots, but is more striking
in the latter. Sequencing depth plays a lesser role in this regard, although it is
observed that higher sequencing depths compensate somewhat for lower replication
levels. For example, the concordance plots show that datasets with 50 replicates
per group may achieve greater concordance with true gene rankings when depths are
above one million as compared to lower.
Based on these results, a recommendation can be made that, when submitting
pilot data to serve as the basis for extrapolation-based statistical power calculations,
researchers should strive to provide data that have a moderately high number of
replicates, even if this requires sacriﬁcing sequencing depth. The accuracy of statistical power calculations may be substantially improved by increasing the number
of replicates in the pilot data, but only marginally aﬀected by increasing sequencing
depth.
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3. MODELING DIFFERENTIAL GENE EXPRESSION FROM
SCRNA-SEQ DATA
Statistical analyses of scRNA-seq data up to this point have been largely limited to
exploratory data analysis tools such as principal component analysis (PCA) and hierarchical clustering. Preliminary investigations into the capabilities of scRNA-seq have
tended to favor such methods in large part for oﬀering interpretable visualizations of
the patterns and underlying structures among collections of individual cells, without
any a priori assumptions or expectations. This kind of bottom-up approach, which
characterizes exploratory data analysis, is par for the course in the early stages of new
technologies. For example, after microarrays were invented in the 1990s, enabling the
ﬁrst gene expression proﬁling experiments on a genomic scale [Schena et al., 1995,
Brown and Botstein, 1999], clustering analyses dominated the results sections of early
manuscripts [Quackenbush, 2001]. In similar fashion, PCA and clustering are now
regularly applied to single-cell gene expression proﬁles to, for example, detect how a
population of cells may be separated into subpopulations of distinct cell types [Shalek
et al., 2013, Dalerba et al., 2011, Islam et al., 2011].
Certainly, exploratory data analysis has an important place in the scientiﬁc procedure [Tukey, 1977]. However, it is classically understood that to be truly comprehensive, statistical analyses of experiments must iterate between preliminary investigations involving exploratory tools and conﬁrmatory tests of concrete hypotheses; it is
from the latter that scientiﬁc conclusions and predictions can be made. For example,
a major goal of statistical inference for bulk RNA-seq data over the past decade has
been the identiﬁcation of genes whose levels of expression diﬀer between phenotypes
or experimental conditions. The objective of these experiments is to test, for each
given gene, whether an observed diﬀerence in read counts between groups is statisti-
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cally signiﬁcant in the presence of biological and experimental variation. There are
many reasons to expect scRNA-seq studies to rapidly move forward into similarly
targeted tests of concrete hypotheses, by way of controlling well-deﬁned conditions
for diﬀerent groups of single cells. For example, drug testing applications are often
interested in the response of diﬀerent cell types to varying drug treatments; cancer
researchers may like to investigate the eﬀect of knocking out an oncogene on the
rest of the transcriptome; others may want to detect the most important genes that
drive the transcriptional changes between cells at separate stages of diﬀerentiation.
Applications such as these abound in the scRNA-seq literature, but presently remain
largely caught in the realm of clustering and hypothesis generation.

3.1

The Stochastic Nature of Gene Expression
Most of the existing scRNA-seq studies that attempt to formally test for dif-

ferential expression between experimental conditions have simply adopted standard
methods developed in the context of bulk cell RNA-seq. Unfortunately, there are
caveats to be raised regarding the rote application of bulk tools to single-cell data
in a one-size-ﬁts-all fashion. Bulk RNA-seq aggregates gene expression across whole
populations of cells (Figure 1.1), obscuring some unique features that only manifest
at the cellular level. In particular, gene expression in individual cells is inherently a
dynamic process with unknown rates of activity [Elowitz et al., 2002, Raj and van
Oudenaarden, 2008, McAdams and Arkin, 1997]. This phenomenon, dubbed ‘stochasticity’ in scientiﬁc jargon, refers to how transcription occurs not uniformly, but often
in bursts of individual genes or of coordinated gene networks [Kaufmann and van
Oudenaarden, 2007, Marinov et al., 2014, Munsky et al., 2012, Sanchez and Golding, 2013, Wills et al., 2013]. Rather than exhibit constant gene expression, levels of
mRNA molecules monitored in real time have been found to ﬂuctuate as if the genes
themselves were randomly and unpredictably switching back and forth between active
and inactive states [Golding et al., 2005]. Single cells that are captured for sequenc-
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ing are invariably a snapshot of these stochastic ﬂuctuations. As a result, scRNA-seq
data are frequently seen to exhibit genes that may have moderate to strong expression in some cells, but very little to no expression in other cells (Figure 3.1). This
feature has been previously referred to as ‘dropout events’ [Kharchenko et al., 2014]
or ‘bimodal expression’ [Shalek et al., 2013].
In addition to gene expression stochasticity driving observed bimodality in the
data, there is also a technical component contributing to the eﬀect. Single cells oﬀer
tens of thousands of times less input RNA than bulk tissue samples, often in the
range of picograms rather than the usual nanograms or micrograms. These minimal
amounts of starting RNA can lead to transcripts either being missed in the reversetranscription stages of sample preparation, or not being present in suﬃcient quantity
to be detected by the sequencing machine. In addition, extremely low levels of input
material result in samples being much more likely to degrade or to be perturbed
by any of the many stages of the experimental process, from sample preparation to
sequencing. Altogether, the eﬀect of both biological stochasticity and of technical
challenges is that many genes, while potentially expressed in truth, do not become
represented in the data in expected quantities.
A second important feature that becomes manifest in single cell data is the eﬀect
of the cell cycle, deﬁned as a series of steps that deﬁne the life span of the cell.
These steps are deﬁned by the following phases: the ﬁrst and longest growth phase
(G1) when cells grow larger and increase their production of proteins and ribosomes
in preparation for DNA synthesis; the synthesis phase (S) when cells replicate a
complete copy of their DNA; the second growth phase (G2) when cells continue to
prepare metabolically for mitosis; and ﬁnally, mitosis (M) during which active cell
division occurs (Figure 3.2). Given the highly regulated and controlled nature of
this process, the cell cycle stage is known to aﬀect the transcriptional activity of
cells in global, non-trivial ways. The impact this has on observed gene expression in
captured cells may pose a substantial confounding eﬀect when testing other factors
of interest. There is evidence that the high variability found in mRNA levels of single
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Figure 3.1. Violin plots of log counts for ﬁve randomly selected genes
across 399 human prostate cells demonstrate the bimodality, or ‘dropout
events’, commonly seen in scRNA-seq data. This bimodality may arise
from both biological as well as technical sources. Each point represents
a cell’s expression value for a given gene, with a vertical jitter added for
visual clarity. The lines display a smoothed kernel density for visualizing
the overall distribution of expression values.

yeast cells is driven not only by stochastic bursts of gene expression, but in no small
part also by transcriptional diﬀerences between phases [Zopf et al., 2013]. Deliberate
perturbations of the cell cycle by inhibition of cell cycle regulator proteins have been
observed to substantially aﬀect phenotypes such as nuclear and cell morphology [Chen
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et al., 2013]. Moreover, cell cycle has been linked to fundamental biological processes
such as diﬀerentiation [Singh et al., 2013, Pauklin and Vallier, 2013] and oncogenesis
[Bar-Joseph et al., 2008, Kastan and Bartek, 2004]. Altogether, cell cycle is a key
driver of cell-to-cell heterogeneity.

Figure 3.2. The cell cycle is a series of steps that deﬁne the life span of the
cell, and are divided into the following phases: the ﬁrst and longest growth
phase (G1) when cells grow larger and increase their production of proteins
and ribosomes in preparation for DNA synthesis; the synthesis phase (S)
when cells replicate a complete copy of their DNA; the second growth
phase (G2) when cells continue to prepare metabolically for mitosis; and
ﬁnally, mitosis (M) during which active cell division occurs.

3.2

Existing Methods for Bulk RNA-Seq Data
The diﬀerential expression analysis of tissue-level RNA-seq data has proliferated

in the scientiﬁc literature, and is now a routine procedure applied to a wide variety of
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organisms for the purpose of testing a large range of biological and experimental effects. In large part, the ubiquity of these analyses is owed to the success and useability
of several well-established statistical methods for testing diﬀerential gene expression;
the most notable of these are implemented in the R packages edgeR [Robinson et al.,
2010] and DESeq [Anders and Huber, 2010].
The statistical methods that comprise edgeR were originally presented in Robinson and Smyth [2008]. The authors model the read counts of each gene across multiple
samples using a negative binomial distribution, a departure from previously used Poisson models which fail to account for the increased variance observed with RNA-seq
data. The negative binomial dispersion parameter is estimated using a modiﬁcation
to the conditional maximum likelihood (CML) method, based on an adjustment of
the data to being of equal library sizes. This adjustment allows the CML machinery
to be used for dipersion estimation, and also aﬀords a test for diﬀerential expression
between experimental conditions using an exact test. Robinson and Smyth [2007]
build on this by allowing for both a global estimation of a common dispersion across
all genes, as well as a per-gene disperison estimation using conditional weighted likelihood to shrink each individual dispersion towards the global value. McCarthy et al.
[2012] extends these negative binomial methods for diﬀerential expression to generalized linear models (GLMs), allowing for the testing of more complex experimental
designs.
Anders and Huber [2010], the authors of DESeq, also model the counts of each
gene via a negative binomial distribution; however, they take a diﬀerent approach
to estimating the dispersion parameter. Rather than assuming the typical variancemean relationship of the negative binomial distribution, as σ 2 = μ + φμ2 where φ is
the dispersion parameter (as done in edgeR), the authors take a data-driven approach
to link the variance and mean. Speciﬁcally, the variance and mean are instead linked
by a smooth local regression. Diﬀerential expression testing proceeds via an exact
test, similar to that of Robinson and Smyth [2008]. The methods are updated in Love
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et al. [2014] to include shrinkage estimation using empirical Bayes priors as well as a
GLM framework, and implemented in the R package DESeq2.

3.3

Accounting for Bimodality
Regardless of the source of bimodality in single-cell gene expression measurements,

whether technical or biological, it is important to account for this structure of the
data when testing for diﬀerential expression. Previously, Kharchenko et al. [2014]
developed a three-component mixture model to describe the dropout prevalence of
scRNA-seq data, and then employed a Bayesian approach to test for diﬀerential expression. However, this method is limited to testing between two groups, restricting
its applicability to more complex designs or experiments with multiple conditions.
McDavid et al. [2013] accounted for bimodality also by using a mixture model, this
time in a GLM framework, but the model was developed for the continuous measurements generated from single-cell quantitative PCR expression measurements, and do
not extend to the count data of scRNA-seq.
The approach proposed here is to employ a zero-inﬂated negative binomial (ZINB)
model to account for the salient features of scRNA-seq data while testing for diﬀerential gene expression. In particular, the zero-inﬂated component attempts to capture
the bimodality of scRNA-seq data which often manifests as a prevalence of excess
zeros. The remaining observations are modeled as a separate component using the
negative binomial distribution, appropriate for RNA-seq count data. Finally, the
GLM testing framework allows for the testing of covariates and hence can accommodate complex experimental designs.
As depicted in Table 1.1, RNA-seq data are represented as a matrix of read counts,
and are frequently modeled using a negative binomial (NB) distribution. The NB
model appropriately accommodates the overdispersion typically seen in count data
from biological applications, in which the observed variation is greater than would be
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expected under a more restrictive Poisson model. One common parametrization of
the NB probability mass function is
Γ(y + φ−1 )
f (y; μ, φ) = P (Y = y) =
Γ(φ−1 )Γ(y + 1)



1
1 + μφ

φ−1 

μ
−1
φ +μ

y
,

(3.1)

where φ is the dispersion parameter, E[Y ] = μ, and Var[Y ] = μ + φμ2 . Notice
that when φ = 0, this reduces to the Poisson distribution. In the speciﬁc context of
RNA-seq, this distribution is used to model the counts ygi of a single gene g across n
samples as
ygi ∼ N B(μgi = mi λgi , φg ), i = 1, ..., n.

(3.2)

The mean parameter μgi is a product of mi , the total number of reads mapped to
sample i (the library size), and λgi , the fraction of all reads from sample i that
originate from gene g.
In experimental contexts with non-normally distributed response data, it is useful
to use generalized linear models (GLMs) to model the dependence of the observed
data on a vector of covariates [Nelder and Wedderburn, 1972, McCullagh and Nelder,
1989]. This dependence is described via the log-linear model
log(μgi ) = xTi βg + log(mi ),

(3.3)

where xi is the covariate vector for the ith sample, βg is the vector of regression
coeﬃcients for gene g, and the library size mi is used as an oﬀset.
The previously described bimodality seen in scRNA-seq data manifests itself as
an excess of zeros which cannot be fully explained by the NB distribution alone,
even with the sophisticated dispersion estimation methods of edgeR and DESeq. The
proposed alternative is to employ a zero-inﬂated count model [Lambert, 1992], which
speciﬁes two components which may give rise to zero observations: a point mass
of zeros arising with probability π, and a count distribution fc (y) by which zeros
may also be observed. fc (y) is NB for these purposes but in general may be any
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count distribution such as Poisson or binomial. The zero-inﬂated count model with
regressors may be written as a mixture model of the form
f (y; x, β) = π · I{0} (y) + (1 − π) · fc (y; x, β),

(3.4)

where I{0} (y) is an indicator of a zero observation. The corresponding mean of these
observations is
E[f (y; x, β)] = π · 0 + (1 − π) · E[fc (y; x, β)]
= (1 − π) · exp(xT β),

(3.5)

using the canonical log-link of the count component GLM. Model (3.4) may equivalently be written in the following form, which more clearly demonstrates the two
possible sources of zeros:
⎧
⎨ π + (1 − π) · f (0; x, β) if y = 0
c
f (y; x, β) =
⎩ (1 − π) · f (y; x, β)
if y > 0.
c
The probability of the zero component π may be either set as a constant, or modeled
with its own GLM g(π) = wT γ, most often with a logit link. The covariates w for
the zero component are not necessarily distinct from the covariates β of the count
component, and in the simplest case consists of only an intercept.
Note that the zero-inﬂated count model is not the same as the hurdle model originally proposed by Mullahy [1986], though they may appear similar at ﬁrst glance.
The hurdle model also consists of two components, but in this case, the zero component is used to model all the zeros, leaving a truncated count component to describe
the rest of the positive observations. Thus, the distinction lies in the interpretation of
how zeros are generated. While the zero-inﬂated model allows for a both a ‘structural’
source as well as a “sampling” source of zeros, the hurdle model assumes all the zero
observations to originate from a ‘structural’ source and that the remaining ‘sampling’
process is strictly positive. The nature of scRNA-seq data favors the interpretation
of the zero-inﬂated model; hence, this is the method of choice.
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To set up the log-likelihood function for gene g, ﬁrst deﬁne zgi as an indicator of
a zero count for sample i. That is,
⎧
⎨ 1 if y = 0
gi
zgi =
⎩ 0 if y > 0.
gi
The likelihood of a single observation ygi may be written
f (ygi ) = [πg + (1 − πg )fc (0)](1−zgi ) × [(1 − πg )fc (ygi )]zgi .

(3.6)

Given regression parameters γg and βg for the zero and count components, respectively, such that π = π(xi , γg ) and fc (ygi ) = fc (ygi ; xi , βg ), the log-likelihood is
n

L(γg , βg ) =

(1 − zgi ) · log [πg (xi , γg ) + (1 − π(xi , γg )) f2 (0; xi , βg )]
i=1
n

zgi · log [(1 − π(xi , γg ))f2 (ygi ; xi , βg )] .

+

(3.7)

i=1

For the purposes presented here of testing diﬀerential gene expression, the zero component π(xi , γg ) is modeled as intercept-only, and the count component fc (ygi ; xi , βg )
is taken to be a negative binomial regression model with single covariate βg corresponding to the treatment group. For a particular gene g, the hypothesis of interest
is
H0 : βg = 0

(3.8)

Ha : βg = 0.
All parameters are estimated by maximum likelihood using numerical optimization
methods such as the Broyden-Fletcher-Goldfarb-Shanno (BFGS) algorithm [Broyden,
1970]. Signiﬁcance tests for each parameter may be carried out using the Wald test,
or for nested models using a likelihood ratio test [McCullagh and Nelder, 1989]. Given
the tens of thousands of individual gene tests for a complete gene expression dataset,
false discovery rate (FDR) is controlled using the Benjamini Hochberg (BH) procedure
[Benjamini and Hochberg, 1995].
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3.4

Accounting for Unmeasured Cell Cycle Eﬀects
One major challenge in characterizing the eﬀect of cell cycle on observed gene

expression is that of measuring the cell cycle stage itself. Experimental approaches
to accomplish this are varied. One method is to induce cell-cycle arrest, either by
depleting factors driving progression between stages, by chemical treatments, or by
inhibiting key pathways [Meijer, 1996]. Other techniques include using centrifugation
to stratify cells by size (and by proxy, their stage) [Ly et al., 2014], or using ﬂow
cytometry to measure DNA content based on retention of a dye [Nunez, 2001]. Major
drawbacks to these approaches include the labor intensiveness of the procedures, as
well as potential side eﬀects that could disrupt the biological system in undesirable
ways. For these reasons, most single-cell gene expression datasets that do not directly
aim to study the cell cycle are generally not accompanied by cell cycle stage annotations; that is, it is still uncommon for experimenters to annotate cell cycle stages
as a matter of course. Consequently, though it is generally recognized that cell cycle
eﬀects exist and may be substantial, the magnitude of cell-cycle distortions to gene
expression has not been precisely characterized, nor is it well-understood which genes
are aﬀected. The drawbacks of experimental approaches to cell cycle characterization
motivate the application of statistical tools that can achieve the same goals.
One apparent approach to inferring cell cycle information is by using unsupervised classiﬁcation methods to explicitly predict the unobserved cell cycle stage on
the basis of the cells transcriptome proﬁle. To evaluate the eﬀectiveness of a range of
established methods toward this objective, Scialdone et al. [2015] applied each chosen method to the same scRNA-seq training dataset in which the cell cycle stages
were known, and assessed their predictive performance on a variety of labeled test
datasets. The methods evaluated include the following: a random forest classiﬁer;
logistic regression, both with and without a lasso penalty; support vector machines;
PCA-based classiﬁcation; and a custom algorithm based on the idea of selecting pairs
of genes whose relative expression changes signs across cell-cycle stages. Rather than
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building the algorithms using the full transcriptome consisting of all the genes, the
authors construct a set of cell cycle marker genes whose variation in the training
dataset exceed an established threshold of technical noise. The idea is that by using
only the expression levels of the selected cell cycle marker genes as training data,
the algorithms are built in a way that is informed primarily by the cell cycle rather
than other artifacts. The results of Scialdone et al. [2015] could ostensibly be used to
inform the choice of how best to assign cell cycle stages to each cell.

3.4.1

Methods Employing Control Genes

Often, however, the cell cycle itself is of no interest and is considered primarily a
nuisance factor. In these cases, rather than explicitly assign cell cycle stages to cells,
an alternative might be to estimate and then remove the eﬀect of cell cycle variation
from the data altogether. This approach was ﬁrst proposed by Gagnon-Bartsch and
Speed [2012] to correct for hidden factors present in microarray data, such as batch
eﬀects from sample processing or unwanted biological variation. The correction of
these factors is presented as a means to more clearly identify diﬀerential expression
signatures from a primary factor of interest, such as experimental conditions or biological groups. Crucially, the authors make use of negative control genes, which are
deﬁned as genes that are both uninﬂuenced by the primary factor of interest, while
also being positively inﬂuenced by the unwanted factor(s). With this deﬁnition, it
may be assumed that variation observed in the negative control genes is attributed
to the unwanted factor, rather than the factor of interest.
Brieﬂy, the method of Gagnon-Bartsch and Speed [2012] involves modeling the
expression data Y as
Y = Xβ + Zγ + W α + ,

(3.9)

where X, Z, and W are matrices whose columns represent the factors of interest, the
(optional) observed covariates, and the unobserved covariates, respectively. When
the estimation is restricted to the set of negative control genes, selected a priori on
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the basis of being uninﬂuenced by the factors of interest X, the coeﬃcients for β are
by deﬁnition equal to zero and the corresponding term goes away. With or without
Z, factor analysis is used to produce an estimate Ŵ for W , which may then be
substituted back into the full model in order to estimate coeﬃcients β for X.
The method of Gagnon-Bartsch and Speed [2012] is speciﬁcally designed for the
purposes of diﬀerential expression testing in a microarray regression context. Along
with that, the authors strongly recommend against using it naively towards a global
adjustment of expression values. This latter goal has been addressed recently in
Buettner et al. [2015], who draw on the idea in Gagnon-Bartsch and Speed [2012] of
using negative control genes, but with the intent of explicitly recovering a corrected
gene expression matrix free of unwanted variation. Most relevant for the purposes
here, the method in Buettner et al. [2015] was developed to deal in particular with
the presence of confounding cell cycle eﬀects arising from single-cell gene expression
data.
Speciﬁcally, in the ﬁrst step of Buettner et al. [2015], the expression proﬁles of a
set of annotated cell cycle genes are used to recover a covariance matrix Σ, which can
be said to describe the cell-to-cell variation attributed to the cell cycle. In the second
step, a linear mixed model (3.10) is ﬁt to the expression values of each gene, breaking down sources of expression variance attributed to technical noise (δg2 ), biological
variability (vg2 ), and the unwanted factor(s) under consideration (σg2 ; i.e. cell cycle).
yg ∼ N (μg , σg2 Σh + vg2 + δg2 ).

(3.10)

Under this variance component model, a residual expression dataset with the eﬀect of
the unwanted cell cycle factor removed may be obtained by employing the predictive
distribution of the cell cycle component with mean ŷi ; residual expression values are
deﬁned as yi∗ = yi − ŷi . The suggested use of this corrected gene expression dataset
is as an input to existing statistical methods for clustering, dimension reduction, and
visualization.
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A major caveat exists with the use of negative control genes in the previously
described methods. That is, the validity of these strategies is entirely predicated
on the negative control genes being both uninﬂuenced by the primary factor(s) of
interest, a well as being indeed inﬂuenced by the unwanted factor. If the negative
control genes are in fact inﬂuenced by the primary factor, their removal will result
in an eﬀect of “throwing the baby out with the bathwater”; that is, variation due to
the primary factor would be removed along with the unwanted factor. Conversely, if
the negative controls do not in fact exhibit the unwanted variation assumed of them,
methods to detect that variation break down. In addition, even if the expression
variance of a control gene is owed to the unwanted variation under consideration,
there is no way to know if it is also inﬂuenced by other, non-cell-cycle eﬀects. In
practice, both of these conditions are diﬃcult, if not impossible, to conﬁdently verify,
rendering these methods hazardous to use.

3.4.2

Surrogate Variable Analysis

Given the shortcomings of the previously discussed approaches and the need to
account for cell cycle eﬀects, we settle on a method called surrogate variable analysis (SVA), originally developed in Leek and Storey [2007] for microarray data and
updated in Leek [2014] to accommodate RNA-seq count data. SVA identiﬁes and
estimates the unwanted eﬀects of all unmeasured confounding factors directly from
the data, and subsequently incorporates these “surrogate variables” into expression
analyses. SVA diﬀers from Gagnon-Bartsch and Speed [2012] and Buettner et al.
[2015] in that it does not attempt to estimate eﬀects from speciﬁc unwanted factors
such as cell cycle, but from all unmeasured factors that exhibit substantial patterns
of variation. Hence, control genes do not need to be speciﬁed and the associated
challenges of their use are avoided as a result. In addition, the method is able to
more ﬂexibly pick up unwanted factors that haven’t been considered. SVA is also
unlike Buettner et al. [2015] in that it does not try to remove unwanted eﬀects from
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the expression data; rather, the estimated eﬀects from unmeasured variables may be
employed as covariates in gene-wise models. This allows the explicit quantiﬁcation of
the diﬀerent eﬀects that detected surrogate variables may have on diﬀerent genes.
The SVA method may be broken down into three steps. First, the method begins
by ﬁtting a simple model containing only the measured variable of interest, given by
yij = μi + fi (xj ) + eij ,

(3.11)

where μi is the baseline expression level of gene i, fi (xj ) is a function describing the
relationship between the primary variable and the outcome, and eij is the random
error term. In practice, fi (xj ) may often be taken as βi xj , where βj is the linear
regression parameter for the primary factor of interest xj . The residual expression
matrix R, with values rij = yij − μ̂i − fˆi (xj ), represents the variation that is left over
after accounting for the primary variable. A singular value decomposition is applied
to R to identify signatures of variation due to any unmodeled factors, in the form of
singular vectors. By deﬁnition, these signatures are independent of the signal due to
the primary variable, as they are derived from the residual matrix with the primary
eﬀect removed. A permutation test is used to determine which of these singular
vectors exhibit signiﬁcantly more variation than would be expected by chance. These
are said to be signiﬁcant signatures of residual unmodeled variation.
Next, for each signiﬁcant signature, a list is obtained of genes that are each signiﬁcantly associated with that signature. These subsets of genes are interpreted to be the
drivers of the expression variability arising from that signature. Third, the original
expression matrix is subset to the list of genes for each signature under consideration.
This reduced expression matrix represents the expression of those genes estimated to
contain the signature of expression heterogeneity. Another singular value decomposition on this reduced expression matrix returns an estimate of the surrogate variable
for that signature.
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Finally, all signiﬁcant surrogate variables may be included as covariates into downstream regression models in the following manner:
K

λki ĥkj + e∗ij ,

yij = μi + fi (xj ) +

(3.12)

k=1

where ĥ are the surrogate variables detected, with associated coeﬃcients λki .

3.5

Simulations
A simulation study was constructed to demonstrate how SVA may be applied in

conjunction with ZINB to account for cell cycle eﬀects and zero-inﬂation when testing
diﬀerential gene expression in scRNA-seq data.
Data were generated to mimic scRNA-seq data using the method described in
Section 2.2. As before, the distributions from which the count data were drawn are
based on parameters sampled empirically from the real human prostate cancer cell
dataset. The data were simulated to exhibit eﬀects arising from a group factor of
primary interest for testing diﬀerential expression, as well as a confounding factor,
called the cell cycle factor for the purposes here. Genewise coeﬃcients for both group
and cell cycle eﬀects were drawn as βgG , βgC ∼ logNormal(2, 1) for DE genes, while
coeﬃcients for non-DE genes were set to 0. The dataset of 10,000 genes consisted of
4000 (40%) genes with a non-zero group eﬀect, and 4000 genes with a non-zero cell
cycle eﬀect. Each cell was randomly assigned to one of two levels of the group factor
and one of three levels of the cell cycle factor. Groups and cell cycles were assigned
such that these variables exhibited a speciﬁed amount of correlation, speciﬁcally ρ =
{0, 0.25, 0.5, 0.8}. Datasets with ρ = 0, for example, exhibit independent assignment
of group and cell cycle levels to samples, whereas a high correlation of ρ = 0.8
indicate greater challenges in diﬀerentiating between group and cell cycle eﬀects in
the testing stage. The number of replicates per treatment group considered are N =
{5, 10, 25, 50, 100, 200}. Five datasets were generated for each combination of N × ρ.
From each dataset, genes whose average count is less than ﬁve were ﬁltered out.
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SVA was applied to each dataset to produce estimates for the cell cycle of each
sample. Figure 3.3 depicts the SVA estimates of cell cycle across correlation settings,
for selected replication levels of 25 and 200 replicates per group. When the cell cycle
and group variables are uncorrelated, SVA estimates are able to clearly separate the
true cell cycle levels. This becomes more diﬃcult as the correlation between variables increase, although the estimates still remain fairly accurate. Even for relatively
small sample sizes such as 25 replicates per group and for high correlations between
variables, SVA performs relatively well.
To test for diﬀerential expression between levels of the primary group factor, edgeR
and ZINB were applied to each dataset, both with and without SVA estimates of cell
cycle incorporated into the design matrix. The methods of DESeq2 and SCDE were
also attempted, but these methods were found to be so computationally intensive as
to be practically intractable for larger replicate sizes; hence, these comparisons were
left out of the analysis.

3.5.1

Simulation Results

Figure 3.4 depicts ROC plots comparing the performance of edgeR and ZINB,
with and without SVA adjustment. For higher levels of replication, 100 and above
in the simulations, the methods are virtually indiscernible; however, for lower levels
of replication, both variations of ZINB outperform both variations of edgeR. This
suggests an advantage that ZINB has over edgeR, in that it explicitly accounts for
the high prevalence of zeros that are characteristic of scRNA-seq data. As mentioned
previously, the genes in these simulated data exhibit the same proportion of zeros as
the real scRNA-seq dataset on which its distributional parameters were based. More
replicates ostensibly compensate for zero-inﬂation, thus erasing the advantage from
ZINB for larger sample sizes. With regards to the SVA adjustment, as correlations
between the group and cell cycle variables increase, the SVA versions of both methods
outperform their non-SVA counterparts. Higher correlations between group and cell
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Figure 3.3. SVA estimates of cell cycle across correlation settings, for
selected replication levels of 25 and 200 replicates per group. Each point
represents the SVA estimate of a cell, and is colored by the true cell cycle.

cycles imply greater confounding between the eﬀects of these variables. In turn, this
leads to greater challenges in detecting diﬀerential expression with respect to the
group factor of primary interest. Incorporating the SVA estimates into GLM-based
methods such as edgeR and ZINB oﬀers a way to adjust for these confounding eﬀects
in a way that improves the statistical power of the primary analysis. The concordance
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plots of Figure 3.5 show results that are consistent with the ROC plots of Figure 3.4.
That is, the advantages of ZINB are most clearly seen in lower replicate numbers,
and the advantages of SVA are more apparent with high levels of correlation between
group and cell cycle variables.
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Figure 3.4. ROC curves that compare ZINB and edgeR, both with and
without SVA adjustment, for each combination of replicates per group
and level of correlation between the group and cell cycle variable.
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Figure 3.5. Concordance plots depicting the similarity in gene rankings
between each method (ZINB and edgeR, both and without SVA adjustment), for each combination of replicates per group and level of correlation
between the group and cell cycle variable.
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3.6

Experimental Data
The performance of ZINB with a surrogate variable cell-cycle adjustment was

tested on real scRNA-seq datasets. While ideally it would be preferable to apply
the developed methods on datasets that have cell cycles annotated, in addition to
another biological factor of interest to be tested for diﬀerential expression, such a
dataset was not available at time of writing. This reﬂects the novelty in the scRNAseq literature of formally testing diﬀerential expression between experimental groups,
much less treating cell cycle as an explicit covariate when doing so. As an alternative,
two datasets are employed, Sasagawa et al. [2013] and Buettner et al. [2015], both
of which have cell cycles measured and annotated, and an artiﬁcial primary factor
establishing diﬀerential expression between two groups in silico was simulated.

3.6.1

Dataset Descriptions

Sasagawa et al. 2013
The Sasagawa et al. [2013] dataset is comprised of 35 mouse embryonic stem
cells (mESCs) whose cell cycles were sorted by DNA content using Hoechst staining,
which enriches the cells in diﬀerent stages of the cell cycle. This resulted in the
identiﬁcation of 20 cells in the G1 cycle, 7 in the S cycle, and 8 in the G2/M cycle. The
original experiment also involved 12 primitive endoderm (PrE) cells that are directly
diﬀerentiated from the embryonic stem cells. However, these belong exclusively to
the G1 cycle, so were excluded in order to avoid unnecessary confounding with the
mESC cell type. Each cell was prepared as a paired-end sequencing library, and all
were sequenced in parallel using the Illumina HiSeq 2000 instrument.
Both the raw and processed data ﬁles are available on the public genomics data
repository Gene Expression Omnibus (GEO), under accession code GSE42268. However, the only processed data that the authors provide had been normalized to FPKM
(fragments per kilobase million) expression values, which are inappropriate for the
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count data methods that would be applied. As it is not valid to simply convert
FPKM values to count values, the raw sequencing ﬁles were obtained and the data
processed into expression values. This entailed aligning raw sequencing reads to the
Mus musculus reference genome using the command line tool bowtie2, sorting and
indexing the aligned reads using the samtools utilities, and ﬁnally expression quantiﬁcation using the summarizeOverlaps function in the R package GenomicAlignments.
The resulting dataset consisted of count expression values of 22,421 genes in 35 cells.
After ﬁltering out genes with average counts of less than 5 across all cells, 13,095
genes remain for analysis.

Buettner et al. 2015
The Buettner et al. [2015] dataset is comprised of 288 mESCs, with 96 cells each
from the G1, S, and G2/M cell cycle stages. Cell cycles were identiﬁed by Hoeschtstaining and subsequently sorted using ﬂow cytometry. Single-cell library preparation
was performed using the Fluidigm C1 system, paired-end libraries generated using the
Illumina Nextera XT kit, and the libraries were sequenced using the Illumina HiSeq
2000 sequencer. Mapping of raw reads was done using the GSNAP/GMAP program, to a
custom mouse genome (mm10; Ensembl GRCm38.pl); mapped reads were quantiﬁed
using the python package HTSeq. The resulting count data are publicly available at
the ArrayExpress archive of functional genomics data, under accession code E-MTB2805. The original count expression matrix consisted of 38,390 genes in 288 cells.
Filtering out genes whose average counts across all cells were less than 5 resulted in
12,938 remaining for analysis.

3.6.2

Data Analysis

The experiments of both Sasagawa et al. [2013] and Buettner et al. [2015] are
focused primarily on demonstrating experimental methods with respect to cell cycle
speciﬁcally; Sasagawa et al. [2013] seeks to demonstrate the ability of their scRNA-
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seq method Quartz-Seq to diﬀerentiate cell cycle phases, and Buettner et al. [2015]
are concerned with removing eﬀects of the cell cycle from the expression data to
more robustly identify true cell subpopulations. Hence, the count data obtained
from these experiments exhibit labels only for cell cycle, and not for any other experimental groups towards which tests for diﬀerential expression could be applied.
To remedy this, artiﬁcial experimental groups are created by imposing diﬀerential
expression in silico. Speciﬁcally, for each dataset, the cells are randomly divided
into two experimental groups, and for 20% of the genes, a fold-change value drawn
from a N (μ = 2, σ = 1) distribution is generated. This lends the speciﬁcation of
“true” diﬀerentially expressed genes, while keeping all other properties of the original
scRNA-seq dataset intact, notably any potential cell cycle eﬀects. SVA was applied
to each dataset to produce estimates for the cell cycle of each cell. To test for differential expression between the artiﬁcial experimental groups, edgeR and ZINB are
applied, both with and without SVA estimates of cell cycle incorporated into the
design matrix.

3.6.3

Sasagawa et al. (2013) Results

Figure 3.6 shows the SVA estimates for each cell in the Sasagawa data, colored
by the true cell cycle stage. There is some separation seen between G2M and the
other stages, but the G1 and S cycles are not cleanly diﬀerentiated. This could be
partly due to the fact that the SVA method does not look for latent variables due to
a speciﬁc, deﬁned factor; that is, the estimates may not be describing cell cycle at
all, but other artifacts in the data. Hence, a clear separation of SVA estimates on the
basis of cell cycle is not to be immediately expected in the real data, and in truth, it
is unknown whether cell cycle eﬀects are present at all.
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Figure 3.6. SVA estimates for each cell in the Sasagawa et al. (2013) data,
colored by true cell cycle. See Figure 3.2 for cell cycle descriptions.

A ROC plot is shown in Figure 3.7, comparing the ability of edgeR and ZINB, with
and without adjustment using the SVA variable, to detect the diﬀerential expression
that were imposed onto the data. Both versions of ZINB perform better than both
versions of edgeR, a result that is consistent with the simulations of Section 3.5 which
suggest that ZINB exhibits more statistical power in datasets of smaller replicates per
group when there are confounding variables present. SVA improves the performance of
both edgeR and ZINB, though the advantage is slight for the latter. The concordance
plot of Figure 3.8 shows similar conclusions; that is, the ranking of genes found by
ZINB variations have higher ﬁdelity with the true gene rankings than those found by
variations on edgeR.
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Figure 3.7. Sasagawa et al.(2013) results. ROC plot for detecting diﬀerential expression between experimental conditions.
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Figure 3.8. Sasagawa et al. (2013) results. Concordance plot depicting
the similarity in gene rankings between each method and the true gene
ranks.
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3.6.4

Buetter et al. (2015) Results

Figure 3.9 shows the SVA estimates for each cell in the Buettner data, colored by
the true cell cycle stage. For these data, the SVA estimates did not seem to detect
the cell cycle at all. As with the Sasagawa et al.(2013) data, the most apparent
explanation is that the cell cycle speciﬁcally is not the most inﬂuential driver of
unwanted variation in the data. In fact, given the small values of the SVA estimates
(mostly ranging from -0.1 to 0.1), it may well be that there do not exist systematic
confounding variables with large enough eﬀects to be picked up by SVA at all. This
interpretation is consistent with the ROC curves (Figure 3.10) and concordance plot
(Figure 3.11) of the Buettner et al. (2015) data, which do not display added beneﬁts
of adding the SVA adjustment to either method. Once again, however, both plots
depict better performance of ZINB variations than edgeR variations, though the ZINB
advantage is smaller here than in the Sasagawa data. This is likely due to the larger
replicate sizes, an eﬀect similarly observed in the simulations of Section 3.5.
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Figure 3.9. SVA estimates for each cell in the Buettner et al. (2015) data,
colored by true cell cycle.
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3.7

Discussion
Single-cell RNA-seq data has been shown to be fundamentally distinct from tissue-

level RNA-seq data in two important respects: highly zero-inﬂated expression values,
and the confounding presence of cell cycle stage. Statistical methods for the detection of diﬀerential gene expression in scRNA-seq data is underdeveloped. Existing
methods originally developed for tissue-level RNA-seq data fail to account for these
anomalies, and their rote application to single-cell data consequently fall short. The
two strategies posed here work in tandem to address these special features. Surrogate
variables are estimated directly from the data, and serve as covariates that account
for the unwanted variation from latent factors (i.e. cell cycle). Subsequent inclusion
of these surrogate variables into a zero-inﬂated negative binomial model is used to
estimate and test for diﬀerential gene expression, in light of both the excess of zero
counts as well as the unwanted eﬀects from factors such as cell cycle.
Through simulations, ZINB has been shown to outperform the standard bulk tissue method of edgeR when replicate sizes are lower, presumably as higher replication
levels are able to compensate somewhat for zero-inﬂation. Furthermore, the incorporation of SVA into ZINB and edgeR models improves detection capabilities of both
methods. This is particularly true when there is a high correlation between cell cycle stage and the primary group factor, a situation which otherwise poses distinct
challenges to testing diﬀerential gene expression by confounding the primary signal
of interest. It is to be noted that in these simulations, edgeR was chosen as the only
competitor to ZINB, due to signiﬁcant computational diﬃculties of existing methods
that attempt to achieve the same goal, namely DESeq and SCDE, when replication
levels are even moderately high. Hence, ZINB with the addition of SVA may be seen
as a suitable alternative to existing bulk methods when analyzing scRNA-seq data.
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4. SUMMARY
4.1

Summary of Work
Single-cell RNA-sequencing is a revolutionary new frontier, both for biologists

as well as statisticians. For well over a decade, the measurement of genome-wide
transcription information (RNA-seq) of populations of cells has driven an important
part of genomic research. Today, RNA-sequencing of bulk tissues is increasingly
aﬀordable and ubiquitous, even routine, and enjoys a level of standardization that
continues to push the rate and reproducibility of these experiments. The emerging
ability to ask questions of individual cells has already shown tremendous promise
in extracting new biological information that eluded scientists even just a few years
ago. However, despite the recent surge in research investigations aiming to proﬁle
the molecular content of single cells, the ﬁeld has yet to mature in many important
aspects. The purpose of this dissertation is to shed light on critical issues in the
design and statistical analysis of single-cell RNA-sequencing experiments, and to oﬀer
guidelines and strategies on how to proceed on both fronts.

4.1.1

Design of scRNA-Seq Experiments

Currently, no clear guidelines exist for the design of scRNA-seq experiments,
speciﬁcally as it pertains to the choice of sequencing depth and replication levels.
In Chapter 2, it is explained how the depth at which a sample is sequenced impacts
the robustness of its gene expression quantiﬁcation. Higher sequencing depths compensate for inadequacies of the technology and ensure that an adequate number of
molecules are represented in the sequencing library. Despite these beneﬁts, however,
researchers would be remiss to simply sequence as much as possible. There exists a
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point at which the gains from sequencing more deeply begin to taper oﬀ, as more
reads fail to yield substantially more genomic information. In addition, there is a
practical tradeoﬀ between the number of biological replicates to include in an experiment and how deeply to sequence those replicates; that is, a choice must be made as
to whether to sacriﬁce sequencing depth in favor of including more replicates, or vice
versa. Simulations were carried out to shed light on this question, by investigating
the eﬀect of diﬀerent combinations of sequencing depths and replication levels on the
detection of diﬀerential gene expression. The simulations were carried out in two
ways: down-sampling from a real scRNA-seq dataset consisting of two experimental
groups, and generating fully simulated data to investigate the eﬀects of larger sample sizes than were available from the real data. In both cases, it was found that
increasing the number of replicates substantially and consistently increases statistical
power; by contrast, increasing the sequencing depth has only a marginally positive
eﬀect beyond the lowest depths.
While these results oﬀer general guidelines, also presented in Chapter 2 is an
interactive tool, called scDesign, that makes experiment-speciﬁc recommendations
that are informed by user-submitted pilot data. These pilot data may be either a
small-scale portion of a planned experiment or related prototype data from similar
existing experiments. In either case, the recommendation is for researchers to provide
pilot data that contain a moderately high number of replicates to ensure that features
of the data may be adequately captured, even if this requires sacriﬁcing sequencing
depth. For each of a range of experimental designs characterized by a sequencing
depth and a replication level, scDesign estimates the experiment-wide statistical
power in one of two ways: a theoretical procedure based on that of Bi and Liu [2016],
and a simulation-based empirical calculation. In addition, the projected cost of each
experimental design will be calculated, based on a cost function with parameters
guided by real experiments. This tool is available both as the R package mentioned,
and is also implemented for interactive use as a Shiny application, located at https:
//github.com/fayezor/scDesignApp.
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4.1.2

Modeling Diﬀerential Gene Expression from scRNA-Seq Data

While the RNA-seq data of bulk tissue and single cells look structurally the same that is, they both contain the expression measurements of tens of thousands of mRNA
transcripts obtained across a number of biological replicates - the similarity proves
superﬁcial upon closer examination. In Chapter 3, several important ways in which
single cell expression data diﬀer from bulk expression measurements on populations
of cells are detailed. First, single cells that are captured for sequencing are invariably
snapshots of “stochastic” ﬂuctuations in transcription. This phenomenon is masked
in bulk data, but manifests itself as an abundance of zeros in single-cell data, where
many genes exhibit moderate to strong expression in some cells, but drop out in
other cells. Contributing to the observed zero-inﬂation is also a technical component:
minimal amounts of starting mRNA in single cells can lead to transcripts being missed
in sample preparation or undetected in the sequencing process. A second important
feature that presents itself at the single-cell level is the eﬀect of the cell cycle, which
has been known to aﬀect the transcriptional activity of cells in global, non-trivial
ways.
The approach proposed in Chapter 3 is to employ a zero-inﬂated negative binomial distribution for the purpose of modeling diﬀerential gene expression in scRNAseq data. The zero-inﬂated component would capture the prevalence of excess zeros,
while the negative binomial component would model the remaining counts with a distribution appropriate for RNA-seq count data. To account for the unmeasured eﬀects
of cell cycle stage on gene expression, an application of surrogate variable analysis
[Leek and Storey, 2007] was proposed. SVA is capable of estimating the eﬀects from
unwanted factors directly from the data, avoiding the risk inherent in specifying control genes, and allows the incorporation of estimated eﬀects directly as covariates in
subsequent models. A simulation study was performed to demonstrate how SVA may
be applied in conjunction with ZINB to improve the detection of diﬀerential gene
expression in data simulated to display the features in question. It was observed that
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when the cell cycle is correlated with the group factor of primary interest, SVA estimates are able to clearly distinguish true cell cycles. Accordingly, the incorporation
of SVA covariates into subsequent models improves diﬀerential expression detection
capabilities over corresponding models without SVA adjustment. Both variations of
ZINB, with and without SVA, outperform both variations of the accepted standard
method of edgeR. However, this advantage disappears for higher levels of replication,
presumably because larger samples are able to compensate for loss of statistical power
due to zero-inﬂation.

4.2

Future Work
Experiments involving thousands, even tens of thousands, of cellular replicates

will soon be the norm in the single-cell ﬁeld, as technologies become ever more massively parallel and platforms ﬁnd ways to exploit economies of scale. 96-well plates
for the isolation and processing of cells is the current standard, but 800-well systems
are already making their way into cutting edge facilities. Chapter 2 was focused on
experimental design speciﬁcally as it pertains to the choice of sequencing depth and
replicate number, parameters which impact the ability to extract genomic information from sequence data. These questions are necessary for establishing experimental
standards for the budding technology, and to encourage thoughtful planning for researchers who face limits to their resources. However, as costs continue to plummet
and scientists may be freed to think beyond the constraints of cellular replicates
and sequencing depths, these considerations will give way in immediate importance
to more foundational notions of experimental design. For example, the necessity of
replication is driven by the presence of biological variability, which exists not just from
cell to cell, but also from organism to organism and tissue to tissue. Currently, the
unit of direct interest is limited to the individual cell, while other layers of biological
variability, originating from the tissues and whole organisms from which those cells
are selected, are routinely neglected. The most commonly reported experiments are
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performed on samples of cellular replicates with no information on tissue or organism replicates; that is, the cells may as well originate from a single tissue in a single
organism. As long as experimenters seek to characterize cells in reproducible ways,
deliberate replication in these other layers is essential.
Throughout this work, the target task of statistical inference was the detection of
genes that exhibit diﬀerential expression across experimental groups. The intended
focus was on improving tests of speciﬁc hypotheses, contrasting these with the unsupervised exploratory data analysis procedures that are currently much more prevalent
in the literature. However, the goals of identifying subpopulations of cells, currently
accomplished through tools such as clustering and PCA, deserve to be revisited in
their own right in order to accommodate them to the unique features of single cell
data. Indeed, it should be recognized that there are pertinent biological questions
that would treat the characterization of cell subpopulations as an end goal, rather
than simply a middle step towards conﬁrmatory statistical tests. Single cell data also
provide unique opportunities to understand cell diﬀerentiation processes that could
elucidate mechanisms behind cell renewal, disease development, and tissue generation. Current data collection methods can be thought of as providing snapshots of
cells frozen in time, which is suﬃcient for singular characterizations but does not lend
itself well to tracing diﬀerentiation behaviors over time. An open statistical problem
is the question of how to make powerful inferences both across and within time points,
and how to identify subsets of genes that follow similar diﬀerentiation patterns.
Aside from these opening questions, there will be continued clariﬁcation of biological goals as the ﬁeld develops. Looking to the future, single-cell experimentation
will inevitably continue to involve more cells from more tissues from more organisms, as well as more kinds of data that beg to be integrated. Needless to say, the
computational weight will continue to rise. For cells easily numbering in the thousands, one must generate easily accessible raw data from the sequencing machines,
process the raw data into sequence information using bioinformatics tools, and infer
some knowledge about the biological property using appropriately developed statis-
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tical methodology. Current data analysis pipelines meant for bulk tissues may not
adequately account for the new errors, biases, and sources of variation that singlecell technologies will carry. Carefully characterizing the issues speciﬁc to single-cell
experimentation is an important goal in future statistical analyses of these data.
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